Gleevec Indigent Patient Program Will Continue After Medicare Rx

Novartis expects more than half of the patients currently receiving free doses of the oral oncologic Gleevec to qualify for the new Medicare prescription drug benefit in 2006

More from Archive

More from Pink Sheet